PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Belimumab

Drugs in development · updated 30 October 2026

Belimumab: clinical trials and development status

Other names and codes: Benlysta

NLM verified identityApproved in the US (FDA)Authorised in the EU (EMA) since 13 July 2011

As of 30 October 2026 Belimumab is in 15 active clinical trials (recruiting or ongoing, phases I–III) for 26 diseases. The most advanced phase is III.

15Active trials
IIIMost advanced phase
26Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Belimumab and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.

DiseaseMost advanced phaseActive trialsReference trial
Interstitial lung diseaseIII4NCT06716606
Connective tissue diseaseIII3NCT06716606
Autoimmune diseaseIII2NCT06572384
Diffuse sclerodermaIII2NCT06716606
Systemic sclerodermaII–III2NCT05878717
Autoimmune thrombocytopenic purpuraIII1NCT05338190
Lung diseaseIII1NCT06572384
Systemic lupus erythematosusII4NCT07138898
Ankylosing spondylitisII1NCT07138898
Antiphospholipid syndromeII1NCT06747312
Arthritis, JuvenileII1NCT07138898
Autoimmune hepatitisII1NCT06381453
DermatomyositisII1NCT07138898
Giant cell arteritisII1NCT07138898
Granulomatosis with polyangiitisII1NCT07138898
Lupus nephritisII1NCT07340463
Membranous glomerulonephritisII1NCT03949855
Nephrotic syndromeII1NCT03949855
Polymyalgia rheumaticaII1NCT07138898
PolymyositisII1NCT07138898
Psoriatic arthritisII1NCT07138898
Rheumatic DiseasesII1NCT07138898
Rheumatoid arthritisII1NCT07138898
SpondylarthritisII1NCT07138898
VasculitisII1NCT07138898
Idiopathic CD4+ lymphocytopeniaI1NCT04097561

Everything on Belimumab

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch